Free Trial

Scilex (SCLX) Competitors

$0.97
+0.01 (+1.04%)
(As of 11/1/2024 ET)

SCLX vs. MKTW, OCS, IMNM, STOK, TRML, ORIC, YMAB, TRDA, ABVX, and HUMA

Should you be buying Scilex stock or one of its competitors? The main competitors of Scilex include MarketWise (MKTW), Oculis (OCS), Immunome (IMNM), Stoke Therapeutics (STOK), Tourmaline Bio (TRML), ORIC Pharmaceuticals (ORIC), Y-mAbs Therapeutics (YMAB), Entrada Therapeutics (TRDA), ABIVAX Société Anonyme (ABVX), and Humacyte (HUMA).

Scilex vs.

MarketWise (NASDAQ:MKTW) and Scilex (NASDAQ:SCLX) are both small-cap business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings.

MarketWise has higher revenue and earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than MarketWise, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MarketWise$448.18M0.42$1.78M$0.087.41
Scilex$46.74M3.99-$114.33M-$1.43-0.68

MarketWise has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, Scilex has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.

MarketWise currently has a consensus target price of $2.50, suggesting a potential upside of 321.51%. Scilex has a consensus target price of $11.33, suggesting a potential upside of 1,066.70%. Given Scilex's stronger consensus rating and higher possible upside, analysts clearly believe Scilex is more favorable than MarketWise.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MarketWise
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Scilex
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Scilex had 6 more articles in the media than MarketWise. MarketBeat recorded 10 mentions for Scilex and 4 mentions for MarketWise. Scilex's average media sentiment score of 0.85 beat MarketWise's score of 0.47 indicating that Scilex is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MarketWise
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Scilex
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

23.0% of MarketWise shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 28.6% of MarketWise shares are held by company insiders. Comparatively, 8.7% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MarketWise has a net margin of 0.80% compared to Scilex's net margin of -233.88%. Scilex's return on equity of 0.00% beat MarketWise's return on equity.

Company Net Margins Return on Equity Return on Assets
MarketWise0.80% -1.30% 0.91%
Scilex -233.88%N/A -111.82%

MarketWise received 16 more outperform votes than Scilex when rated by MarketBeat users. However, 100.00% of users gave Scilex an outperform vote while only 65.00% of users gave MarketWise an outperform vote.

CompanyUnderperformOutperform
MarketWiseOutperform Votes
26
65.00%
Underperform Votes
14
35.00%
ScilexOutperform Votes
10
100.00%
Underperform Votes
No Votes

Summary

Scilex beats MarketWise on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCLX vs. The Competition

MetricScilexBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$186.31M$3.16B$5.40B$8.53B
Dividend YieldN/A1.77%5.13%4.14%
P/E Ratio-0.6812.18115.5615.18
Price / Sales3.99332.351,484.3492.77
Price / CashN/A148.6339.6634.07
Price / Book-0.884.024.665.02
Net Income-$114.33M-$42.25M$119.06M$225.46M
7 Day Performance12.77%8.06%0.80%0.37%
1 Month Performance10.81%8.71%5.65%3.57%
1 Year Performance-47.49%32.10%36.76%29.44%

Scilex Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCLX
Scilex
2.8666 of 5 stars
$0.97
+1.0%
$11.33
+1,066.7%
-46.3%$186.31M$46.74M-0.6880
MKTW
MarketWise
4.0126 of 5 stars
$0.59
+1.7%
$2.50
+321.5%
-73.3%$187.40M$448.18M7.41578Upcoming Earnings
Gap Up
OCS
Oculis
1.9668 of 5 stars
$17.88
+4.1%
$29.20
+63.3%
+96.5%$724.14M$980,000.00-9.312Gap Down
High Trading Volume
IMNM
Immunome
2.4973 of 5 stars
$11.59
+1.0%
$29.00
+150.2%
+35.2%$695.98M$14.02M-1.5140Short Interest ↓
Gap Up
STOK
Stoke Therapeutics
3.835 of 5 stars
$12.86
+4.0%
$20.83
+62.0%
+215.2%$677.08M$8.78M-5.90100Upcoming Earnings
Positive News
TRML
Tourmaline Bio
3.4393 of 5 stars
$26.30
+3.1%
$64.67
+145.9%
+52.7%$674.33MN/A-7.1544
ORIC
ORIC Pharmaceuticals
4.2103 of 5 stars
$9.41
+0.3%
$18.29
+94.3%
+43.2%$663.78MN/A-5.3880Upcoming Earnings
Analyst Forecast
News Coverage
YMAB
Y-mAbs Therapeutics
3.3056 of 5 stars
$14.74
+1.6%
$21.14
+43.4%
+163.2%$656.96M$84.82M-26.32150Upcoming Earnings
News Coverage
Positive News
TRDA
Entrada Therapeutics
2.4135 of 5 stars
$17.60
+2.7%
$21.50
+22.2%
+13.5%$654.72M$129.01M5.95110Upcoming Earnings
Positive News
ABVX
ABIVAX Société Anonyme
3.3503 of 5 stars
$10.27
-0.5%
$36.50
+255.4%
+5.2%$649.99MN/A0.0061Positive News
High Trading Volume
HUMA
Humacyte
3.1748 of 5 stars
$5.39
+6.7%
$10.00
+85.5%
+170.9%$643.30M$1.57M-4.28150News Coverage

Related Companies and Tools


This page (NASDAQ:SCLX) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners